ReviewJournal of oncology practice2019
Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma.
Review in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma.Frontiers in immunology · 2024Trial
- Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.American journal of hematology · 2022Trial
- Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.Journal of clinical medicine · 2026Article
- Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma.International journal of hematology · 2026Article
- Radiotherapy in addition to systemic therapy reduces the early mortality of angioimmunoblastic T-cell lymphoma.Annals of hematology · 2026Article
- Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma.Blood cancer journal · 2024Article
- Indolent nodal T follicular helper cell lymphomas-A case series.Blood cancer journal · 2024Article
- Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.Clinical and experimental medicine · 2023Review
- Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.Clinical case reports · 2023Article
- Editorial: Case reports in hematological malignancies: 2022.Frontiers in oncology · 2023Article
- Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement.The American journal of case reports · 2022Article
- Angioimmunoblastic T-cell lymphoma with extensive follicular dendritic cell and fibroblastic reticular cell network proliferation mimicking follicular dendritic cell sarcoma: A case report with pathologic, immunophenotypic, and molecular findings.Frontiers in oncology · 2022Article
- Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.Current oncology (Toronto, Ont.) · 2021Review
- Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma.Annals of hematology · 2021Article
- Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma.Frontiers in oncology · 2021Article
- Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study.Frontiers in oncology · 2021Article
- [Clinical characteristics and prognosis in 84 patients with angioimmunoblastic T-cell lymphoma: a single-center analysis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Hypomethylating Agents in Lymphoma.Current treatment options in oncology · 2020Review
- Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.Frontiers in oncology · 2020Article
- Pulmonary Arterial Hypertension as an Unusual Presentation of Angioimmunoblastic T-Cell Lymphoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Patients with angioimmunoblastic T-cell lymphoma (AITL), one of the most common types of peripheral T-cell lymphoma (PTCL), typically present with advanced disease, systemic symptoms, and immune deregulation. Treatment can be challenging owing to frequent relapses after initial and subsequent therapy. The front-line treatment approach currently mirrors the approach used for other nodal PTCLs with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and consideration for autologous stem-cell transplant (SCT). In the relapsed and refractory settings, allogeneic SCT offers the chance for long-term remission. Choice of treatment of relapsed or refractory disease depends on whether an allogeneic SCT is planned. Agents with preferential activity in relapsed or refractory AITL include epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other targeted agents show promise in AITL, including brentuximab vedotin and phosphoinositide-3-kinase inhibitors. Ongoing studies are evaluating new potential targets for AITL, with particular focus on identifying markers of response and resistance. Additional studies are assessing incorporation of novel agents into the front-line treatment of AITL. These studies will lead to more individualized treatment approaches and, ultimately, improved outcomes for patients with AITL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.